Do diabetes drugs work differently in women vs men? A massive real-world study says yes

Type 2 diabetes affects millions worldwide, and controlling it is crucial for longevity: high blood sugar damages blood vessels, hearts, and kidneys over decades. Yet most clinical trials of diabetes drugs have enrolled far more men than women, leaving us uncertain whether these medications work the same way in both sexes. This study addresses a genuine gap by examining whether four second-line diabetes drugs—GLP-1 receptor agonists (like semaglutide), SGLT2 inhibitors (like empagliflozin), DPP-4 inhibitors, and sulfonylureas—have different effects in women versus men in real-world practice.

The researchers used an enormous dataset spanning 5.15 million adults with type 2 diabetes across the US, UK, Germany, and Spain, tracked from 1992 to 2021. They compared each drug head-to-head using sophisticated statistical methods (propensity score-stratified Cox models) designed to mimic what a randomized trial would show by accounting for differences in who chose each drug. This real-world approach is powerful because it captures how these medications actually perform outside controlled clinical settings.

The headline finding: no sex differences in cardiovascular effectiveness. Both women and men saw similar heart-protection benefits from GLP-1 drugs and SGLT2 inhibitors. However, safety outcomes told a different story. When comparing GLP-1 drugs to SGLT2 inhibitors, women using GLP-1 had 39% higher risk of acute pancreatitis (confidence interval 1.13–1.70), whereas men had no elevated risk. Conversely, men on GLP-1 had lower blood pressure (good), while women showed no benefit. These patterns were consistent across multiple drug comparisons, suggesting real biological differences rather than statistical noise.

The study also revealed prescribing inequities: women were less likely to receive GLP-1 drugs (9.28% vs 5.41% of men) and more likely to receive sulfonylureas (50.99% vs 57.10%), despite GLP-1 drugs' superior cardiovascular benefits. This finding implies current practice may disadvantage women.

Limitations are important: This is a preprint (not yet peer-reviewed), which means errors or methodological concerns haven't been vetted by independent reviewers. The observational design cannot prove causation, only association—unmeasured confounders could explain differences. The absolute numbers of some adverse events were small, raising questions about precision. The study is also entirely conducted in high-income countries (US, UK, Europe), limiting generalizability to other populations. Finally, the biological mechanisms behind sex differences remain speculative.

For longevity research, this matters because type 2 diabetes is one of the strongest modifiable risk factors for early death and disability. Personalizing treatment by sex—prescribing GLP-1 drugs cautiously in women with pancreatitis risk, for instance—could improve both lifespan and quality of life. The finding should prompt replication in prospective trials and mechanistic studies to understand *why* pancreatitis risk differs by sex.